The Korea-listed company that makes men's clothes, backs the US-based pharmaceutical company.
Wonpung Mulsan, a Korea-listed company that makes men’s clothes, has helped US-based pharmaceutical company Relmada Therapeutics raise a $3m round.
Wonpung Mulsan was joined in the series A round by Pennsylvania development firms BioAdvance and Ben Franklin Technology Partners of Southeastern Pennsylvania.
Laidlaw & Company was exclusive placement agent for the round.
The initial Series A proceeds will be used to continue the development of LevoCap, a proprietary once-a-day extended release dosage form of the potent opioid levorphanol in a tamper resistant delivery system and for general corporate activities.
